Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LDX+ Venlafaxine · 1 trial · 1 indication
Lisdexamfetamine dimesylate (SPD489) itself is inactive, but following oral administration is converted to the active isomer, d-amphetamine, that is responsible for the drug's therapeutic activity.
d-Amphetamine is the active isomer of Lisdexamfetamine dimesylate (SPD489) and is responsible for the drug's therapeutic activity.
Venlafaxine Hydrochloride is the active ingredient of Effexor XR
Venlafaxine, after oral administration, is metabolized in the liver to an active metabolite, o-Desmethylvenlafaxine.
| Arm | Type | Description |
|---|---|---|
| LDX (SPD489) + Venlafaxine XR (Effexor XR) | EXPERIMENTAL | - |
| Venlafaxine XR + LDX | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LDX + Venlafaxine XR | DRUG | * Day 1-5 LDX 30mg * Day 6-10 LDX 50mg * Day 11-15 LDX 70mg * Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily * Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily * Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily * Day 31-34 Venlafaxine XR 150mg daily * Day 35-38 Venlafaxine XR 75mg daily. |
| Venlafaxine XR + LDX | DRUG | * Day 1-5 Venlafaxine XR 75mg * Day 6-10 Venlafaxine XR 150mg * Day 11-15 Venlafaxine XR 225mg * Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily * Day 21-25 Venlafaxine XR and LDX 50mg daily * Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily * Day 31-34 Venlafaxine XR 150mg * Day 35-38 Venlafaxine XR 75mg. |
Inclusion Criteria: 1. Age 18-45 years 2. Subject is willing to comply with any applicable contraceptive requirements of the protocol and is: * Male, or * Non-pregnant, non-lactating female * Females must be at least 90 days post partum or nulliparous. 3. Female subjects must have a negat...
LDX, or lisdexamfetamine dimesylate, is an investigational small molecule being studied for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and adolescents. It has also been evaluated in healthy volunteers for drug interaction studies. The drug is in Phase 3 clinical development for ADHD.
LDX is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The drug is a small molecule in the psychiatry therapeutic area, targeting Attention Deficit Hyperactivity Disorder (ADHD).
LDX is in Phase 3 clinical development for Attention Deficit Hyperactivity Disorder (ADHD). It has completed Phase 3 trials in adults and adolescents with ADHD, as well as a Phase 1 trial in healthy volunteers. The drug is investigational and not yet approved.
LDX has completed several clinical trials, including NCT00697515, a Phase 3 study in adults with ADHD, and NCT00735371, a Phase 3 study in adolescents with ADHD. A Phase 1 trial, NCT01235338, evaluated co-administration of LDX with venlafaxine XR in healthy volunteers.
Yes, LDX is the same as lisdexamfetamine dimesylate. The drug is referred to by both names in clinical trials, with LDX being the abbreviation used in study titles and descriptions.